Condition: Ophthalmic Surgery · Postoperative Pain Management · Opioid Analgesia · Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
The goal of this clinical trial is to learn if Anrikefon works as well as nalbuphine to control postoperative pain in adults undergoing ophthalmic surgery under general anesthesia. It will also learn about the safety and recovery outcomes of using Anrikefon. The main questions it aims to answer are: * Does Anrikefon provide pain relief that is not inferior to nalbuphine after ophthalmic surgery? * Does Anrikefon cause fewer central side effects, such as sedation or dizziness, compared with nalbuphine? * Does Anrikefon help patients recover and get discharged faster after day-surgery procedures? Researchers will compare Anrikefon to nalbuphine to see if Anrikefon can offer effective and safer perioperative analgesia for ophthalmic day-surgery patients. Participants will: * Receive either an intravenous dose of Anrikefon or nalbuphine during surgery. * Be monitored for pain scores, side effects, and recovery parameters after surgery. * Complete follow-up assessments.
This description comes directly from the study's public registry record.
Xiaoliang Gan, PhD · 0086-13688893908 · ganxl@mail.sysu.edu.cn
Yanling Zhu, MD · 0086-18898600243 · zhuyling8@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Zhongshan Ophthalmic Center, Sun Yat-Sen University | Guangzhou, Guangdong, China | Recruiting |
| The Affiliated Hospital of Yunnan University | Kunming, Yunnan, China | Not Yet Recruiting |
| Eye & ENT Hospital of Fudan University | Shanghai, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07269106